Imunon, Inc. · NASDAQ:IMNN

Imunon — Technical Presentation (March 2025)

4 slides from Imunon's technical presentation, Mar 25, 2025

  1. Slide 1: Investor Call: OVATION-3, Phase 3 Study Design

    Investor Call: OVATION-3, Phase 3 Study Design March 25, 2025 © 2023 IMUNON, Inc. PAGE 1

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement This presentation and any statements made during the presentation contain forward-looking statements related to Imunon, Inc. (“Imunon” or the “Company”) under the “safe harbor” provisions of Section 21E of the Private Securities Litigation Reform Act of 1995. All statements, ot

  3. Slide 3: OVATION-3 Pivotal Trial: Finalized Phase 3 Study Design with FDA

    OVATION-3 Pivotal Trial: Finalized Phase 3 Study Design with FDA Randomized, multicenter Phase 3 trial to evaluate the safety and efficacy of IMNN-001 (100 mg/m2) plus standard of care neoadjuvant and adjuvant chemotherapy (NACT) vs SOC NACT alone 1:1 Randomization Treatment Arms stratified by: Stag

  4. Slide 4: Designed with Operational Flexibility

    Designed with Operational Flexibility Sequence HRD First All Comers Initial Focus on 250 HRD Patients 500 Patients 50% of EOC market All-comers population, 100% EOC market Delayed trigger for all-comers population Biomarker defined subgroup, ~50% HRD Both with high statistical power and high likelih

Imunon — Technical Presentation (March 2025) on 6ix